```
=> d his

     (FILE 'HOME' ENTERED AT 15:11:41 ON 19 NOV 2007)

     FILE 'REGISTRY' ENTERED AT 15:12:03 ON 19 NOV 2007
L1                STRUCTURE UPLOADED
L2              1 S L1 SSS SAM
L3             11 S L1 SSS FULL

     FILE 'CAPLUS, MEDLINE' ENTERED AT 15:14:33 ON 19 NOV 2007
L4              3 S L3
L5              2 S L4 AND PAIN

     FILE 'REGISTRY' ENTERED AT 15:51:39 ON 19 NOV 2007
L6                STRUCTURE UPLOADED
L7              1 S L6
L8             13 S L6 SSS FULL

     FILE 'CAPLUS, MEDLINE' ENTERED AT 15:54:54 ON 19 NOV 2007
L9              3 S L8
```

C:\Program Files\Stnexp\Queries\10583992-a.str





chain nodes :
17 19 20 27 28 29 30 31 32 33 34 35 36 37 38 39 41 42 43 44 45 46 47 48 49 50
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 18 21 22 23 24 25 26 40
chain bonds :
2-19 3-37 4-36 7-42 7-43 8-41 9-44 11-35 12-34 13-20 13-39 14-38 16-17 20-25 21-28 21-46
22-29 22-48 23-30 23-49 25-47 26-27 26-45 30-31 30-33 31-32 31-50
ring bonds :
1-2 1-6 1-15 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 8-16 9-10 9-11 10-14 10-40 11-12 12-13
13-14 14-15 16-18 18-40 21-22 21-26 22-23 23-24 24-25 25-26
exact/norm bonds :
1-15 2-19 5-7 6-10 7-8 8-9 8-16 9-10 9-11 10-14 10-40 11-12 12-13 13-14 13-20 14-15 16-18
18-40 20-25 21-22 21-26 21-28 22-23 22-29 23-24 24-25 25-26 26-27 30-31 30-33 31-50
exact bonds :
3-37 4-36 7-42 7-43 8-41 9-44 11-35 12-34 13-39 14-38 16-17 21-46 22-48 23-30 23-49 25-47
26-45 31-32
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom
13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:Atom 19:CLASS 20:CLASS 21:Atom 22:Atom 23:Atom
24:Atom 25:Atom 26:Atom 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS
35:CLASS

36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:Atom 41:CLASS 42:CLASS 43:CLASS 44:CLASS
45:CLASS 46:CLASS 47:CLASS 48:CLASS 49:CLASS 50:CLASS

C:\Program Files\Stnexp\Queries\10583992-b.str





chain nodes :
17 19 20 27 28 29 30 31 32 33 34 35 36 37 38 40 41 42 43 44 45 46 47 48
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 18 21 22 23 24 25 26 39
chain bonds :
2-19 3-36 4-35 7-41 7-42 8-40 9-43 11-34 12-33 13-20 13-38 14-37 16-17 20-25 21-28 21-45 22-29 22-47 23-30 23-48 25-46 26-27 26-44 30-31 30-32
ring bonds :
1-2 1-6 1-15 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 8-16 9-10 9-11 10-14 10-39 11-12 12-13 13-14 14-15 16-18 18-39 21-22 21-26 22-23 23-24 24-25 25-26
exact/norm bonds :
1-15 2-19 5-7 6-10 7-8 8-9 8-16 9-10 9-11 10-14 10-39 11-12 12-13 13-14 13-20 14-15 16-18 18-39 20-25 21-22 21-26 21-28 22-23 22-29 23-24 24-25 25-26 26-27 30-31 30-32
exact bonds :
3-36 4-35 7-41 7-42 8-40 9-43 11-34 12-33 13-38 14-37 16-17 21-45 22-47 23-30 23-48 25-46 26-44
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:Atom 19:CLASS 20:CLASS 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS 35:CLASS

36:CLASS 37:CLASS 38:CLASS 39:Atom 40:CLASS 41:CLASS 42:CLASS 43:CLASS 44:CLASS
45:CLASS 46:CLASS 47:CLASS 48:CLASS

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:549736 CAPLUS
DOCUMENT NUMBER: 143:60187
TITLE: Method of preparation of new derivative of morphine-6-glucuronide, pharmaceutical composition containing it, and its use for the treatment of pain
INVENTOR(S): Temsamani, Jamal; Lahana, Roger; Mouchet, Patrick
PATENT ASSIGNEE(S): Synt:em, Fr.
SOURCE: Fr. Demande, 19 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2864082	A1	20050624	FR 2003-15160	20031222
FR 2864082	B1	20060310		
AU 2004308720	A1	20050714	AU 2004-308720	20041222
CA 2548921	A1	20050714	CA 2004-2548921	20041222
WO 2005063263	A1	20050714	WO 2004-FR3342	20041222
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1696935	A1	20060906	EP 2004-816470	20041222
EP 1696935	B1	20070404		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
AT 358491	T	20070415	AT 2004-816470	20041222
US 2007116665	A1	20070524	US 2006-583992	20060622

PRIORITY APPLN. INFO.:
FR 2003-15160 A 20031222
WO 2004-FR3342 W 20041222

OTHER SOURCE(S): CASREACT 143:60187; MARPAT 143:60187
GI



I

AB The invention relates to new derivs. I [R1 = (un)branched C1-10-alkyl, optionally substituted with alkyl (optionally containing NH, O, S); R2 = H, (un)branched C1-5-alkyl, aryl heteroaryl, (C1-5-alkyl)aryl (optionally substituted with C1-4-alkyl)] of morphine 6-glucuronide, their method of preparation like their uses in therapy, in particular as analgesics. Thus, morphine-6-glucuronide cysteamine amide I (R1 = CH2CH2, R2 = H) was prepared from morphine 6-glucuronide via amidation with cystamine, NH2(CH2)2SS(CH2)2NH2, in DMF containing EtN(CHMe2)2 and PyBOP followed by reduction with P(CH2CO2H)3 in aqueous MeCN containing catalytic CF3CO2H.

IT 854701-23-8P 854701-25-0P 854701-26-1P
854701-27-2P 854701-28-3P 854701-29-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of new cysteamine derivs. of morphine-6-glucuronide and pharmaceutical compns. for the treatment of the pain)

RN 854701-23-8 CAPLUS

CN β-D-Glucopyranosiduronamide, (5α,6α)-7,8-didehydro-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-yl N-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 854701-25-0 CAPLUS

CN Acetic acid, [[1-O-[(5α,6α)-7,8-didehydro-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-yl]-β-D-glucopyranuronoyl]amino]mercapto- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 854701-26-1 CAPLUS

CN Acetic acid, [[1-O-[(5α,6α)-7,8-didehydro-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-yl]-β-D-glucopyranuronoyl]amino]mercapto-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 854701-27-2 CAPLUS
CN Acetic acid, [[1-O-[(5α,6α)-7,8-didehydro-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-yl]-β-D-glucopyranuronoyl]amino]mercapto-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 854701-28-3 CAPLUS
CN Butanoic acid, 2-[[1-O-[(5α,6α)-7,8-didehydro-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-yl]-β-D-glucopyranuronoyl]amino]-2-mercapto-3-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 854701-29-4 CAPLUS
CN Glycine, N-[4-amino-4-[[1-O-[(5α,6α)-7,8-didehydro-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-yl]-β-D-glucopyranuronoyl]amino]-1-oxobutyl]-D-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 854701-24-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of new cysteamine derivs. of morphine-6-glucuronide and pharmaceutical compns. for the treatment of the pain)
RN 854701-24-9 CAPLUS
CN β-D-Glucopyranosiduronamide, N,N'-(dithiodi-2,1-ethanediyl)bis[(5α,6α)-7,8-didehydro-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.







REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:	2002:675880 CAPLUS
DOCUMENT NUMBER:	137:222015
TITLE:	Pharmaceutical compositions comprising an analgesic molecule linked to a vector that can vectorise said molecule through the hematoencephalic barrier
INVENTOR(S):	Temsamani, Jamal; Rees, Anthony R.; Clair, Philippe
PATENT ASSIGNEE(S):	SYNT:EM, Fr.
SOURCE:	PCT Int. Appl., 28 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	French
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2002067994	A2	20020906	WO 2002-FR667		20020222
WO 2002067994	A3	20031224			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
FR 2821272	A1	20020830	FR 2001-2504		20010223
FR 2821272	B1	20041217			
CA 2438824	A1	20020906	CA 2002-2438824		20020222
AU 2002238687	A1	20020912	AU 2002-238687		20020222
EP 1397161	A2	20040317	EP 2002-704883		20020222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004529886	T	20040930	JP 2002-567359		20020222
US 2004248806	A1	20041209	US 2003-468412		20031222
PRIORITY APPLN. INFO.:			FR 2001-2504	A	20010223
			WO 2002-FR667	W	20020222

AB The invention relates to compds. comprising an analgesic mol. which is selected from morphine and the derivs. and metabolites thereof and which is vectorized by means of its link to a vector such that said analgesic mol. passes through the hematoencephalic barrier. The invention also relates to the use of said compds. for the preparation of medicaments that are used to treat pain. Morphine-6-glucuronide was conjugated to a decapeptide. The conjugated morphine had significantly higher and longer analgesic activity and passed blood brain barrier 100 times more than unconjugated morphine after 60 s perfusion in guinea pigs.

IT 454650-18-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(pharmaceutical compns. comprising analgesic mol. linked to vector for mol. through hematoencephalic barrier)

RN 454650-18-1 CAPLUS

CN L-Phenylalanine, N2-[3-[[2-[[1-O-[(5α,6α)-7,8-didehydro-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-yl]-β-D-glucopyranuronoyl]amino]ethyl]dithio]-1-oxopropyl]-L-arginyl-L-arginyl-L-leucyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-B



L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:518937 CAPLUS
DOCUMENT NUMBER: 127:136035
TITLE: Glycoconjugates of opioids
INVENTOR(S): Cowie, Diana; Valencia Paera, Gregori
PATENT ASSIGNEE(S): Farmhispania, S.A., Spain; Cowie, Diana; Valencia Parera, Gregori
SOURCE: PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Spanish
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9721416	A2	19970619	WO 1996-ES214	19961115
WO 9721416	A3	19970912		
W: CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2211596	A1	19970619	CA 1996-2211596	19961115
EP 816375	A1	19980107	EP 1996-938222	19961115
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 10513485	T	19981222	JP 1996-521758	19961115
PRIORITY APPLN. INFO.:			ES 1995-2346 A	19951129

OTHER SOURCE(S): MARPAT 127:136035

AB Glycoconjugates of biol. active opioids were prepared which have at least one residue of carbohydrate linked to the opioid via an O- or C-glycoside bond. Thus, 6-morphinyl-β-D-glucopyranoside acetate was prepared by reaction of tetra-acetyl-α-D-glucopyranosyl bromide with 3-O-acetylmorphine, followed by saponification with MeONa-MeOH.

IT 192768-56-2P 192768-57-3P 192769-04-3P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of glycoconjugates of opioids)

RN 192768-56-2 CAPLUS

CN β-D-Glucopyranosiduronamide, (5α,6α)-7,8-didehydro-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-yl N-octyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192768-57-3 CAPLUS

CN β-D-Galactopyranosiduronamide, (5α,6α)-7,8-didehydro-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-yl N-octyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192769-04-3 CAPLUS

CN β-D-Glucopyranosiduronamide, (5α,6α)-7,8-didehydro-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-yl N-octyl-, monoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 192768-56-2
CMF C31 H44 N2 O8

Absolute stereochemistry.



CM 2

CRN 64-19-7
CMF C2 H4 O2



L9 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:549736 CAPLUS
DOCUMENT NUMBER: 143:60187
TITLE: Method of preparation of new derivative of morphine-6-glucuronide, pharmaceutical composition containing it, and its use for the treatment of pain
INVENTOR(S): Temsamani, Jamal; Lahana, Roger; Mouchet, Patrick
PATENT ASSIGNEE(S): Synt:em, Fr.
SOURCE: Fr. Demande, 19 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2864082	A1	20050624	FR 2003-15160	20031222
FR 2864082	B1	20060310		
AU 2004308720	A1	20050714	AU 2004-308720	20041222
CA 2548921	A1	20050714	CA 2004-2548921	20041222
WO 2005063263	A1	20050714	WO 2004-FR3342	20041222
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1696935	A1	20060906	EP 2004-816470	20041222
EP 1696935	B1	20070404		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
AT 358491	T	20070415	AT 2004-816470	20041222
US 2007116665	A1	20070524	US 2006-583992	20060622

PRIORITY APPLN. INFO.: FR 2003-15160 A 20031222
WO 2004-FR3342 W 20041222

OTHER SOURCE(S): CASREACT 143:60187; MARPAT 143:60187
GI



I

AB The invention relates to new derivs. I [R1 = (un)branched C1-10-alkyl, optionally substituted with alkyl (optionally containing NH, O, S); R2 = H, (un)branched C1-5-alkyl, aryl heteroaryl, (C1-5-alkyl)aryl (optionally substituted with C1-4-alkyl)] of morphine 6-glucuronide, their method of preparation like their uses in therapy, in particular as analgesics. Thus, morphine-6-glucuronide cysteamine amide I (R1 = CH2CH2, R2 = H) was prepared from morphine 6-glucuronide via amidation with cystamine, NH2(CH2)2SS(CH2)2NH2, in DMF containing EtN(CHMe2)2 and PyBOP followed by reduction with P(CH2CO2H)3 in aqueous MeCN containing catalytic CF3CO2H.

IT 854701-23-8P 854701-25-0P 854701-26-1P
854701-27-2P 854701-28-3P 854701-29-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of new cysteamine derivs. of morphine-6-glucuronide and pharmaceutical compns. for the treatment of the pain)

RN 854701-23-8 CAPLUS

CN β-D-Glucopyranosiduronamide, (5α,6α)-7,8-didehydro-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-yl N-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 854701-25-0 CAPLUS

CN Acetic acid, [[1-O-[(5α,6α)-7,8-didehydro-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-yl]-β-D-glucopyranuronoyl]amino]mercapto- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 854701-26-1 CAPLUS

CN Acetic acid, [[1-O-[(5α,6α)-7,8-didehydro-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-yl]-β-D-glucopyranuronoyl]amino]mercapto-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 854701-27-2 CAPLUS
CN Acetic acid, [[1-O-[(5α,6α)-7,8-didehydro-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-yl]-β-D-glucopyranuronoyl]amino]mercapto-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 854701-28-3 CAPLUS
CN Butanoic acid, 2-[[1-O-[(5α,6α)-7,8-didehydro-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-yl]-β-D-glucopyranuronoyl]amino]-2-mercapto-3-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 854701-29-4 CAPLUS
CN Glycine, N-[4-amino-4-[[1-O-[(5α,6α)-7,8-didehydro-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-yl]-β-D-glucopyranuronoyl]amino]-1-oxobutyl]-D-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 854701-24-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of new cysteamine derivs. of morphine-6-glucuronide and pharmaceutical compns. for the treatment of the pain)
RN 854701-24-9 CAPLUS
CN β-D-Glucopyranosiduronamide, N,N'-(dithiodi-2,1-ethanediyl)bis[(5α,6α)-7,8-didehydro-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:	2002:675880 CAPLUS
DOCUMENT NUMBER:	137:222015
TITLE:	Pharmaceutical compositions comprising an analgesic molecule linked to a vector that can vectorise said molecule through the hematoencephalic barrier
INVENTOR(S):	Temsamani, Jamal; Rees, Anthony R.; Clair, Philippe
PATENT ASSIGNEE(S):	SYNT:EM, Fr.
SOURCE:	PCT Int. Appl., 28 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	French
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2002067994	A2	20020906	WO 2002-FR667		20020222
WO 2002067994	A3	20031224			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
FR 2821272	A1	20020830	FR 2001-2504		20010223
FR 2821272	B1	20041217			
CA 2438824	A1	20020906	CA 2002-2438824		20020222
AU 2002238687	A1	20020912	AU 2002-238687		20020222
EP 1397161	A2	20040317	EP 2002-704883		20020222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004529886	T	20040930	JP 2002-567359		20020222
US 2004248806	A1	20041209	US 2003-468412		20031222
PRIORITY APPLN. INFO.:			FR 2001-2504	A	20010223
			WO 2002-FR667	W	20020222

AB The invention relates to compds. comprising an analgesic mol. which is selected from morphine and the derivs. and metabolites thereof and which is vectorized by means of its link to a vector such that said analgesic mol. passes through the hematoencephalic barrier. The invention also relates to the use of said compds. for the preparation of medicaments that are used to treat pain. Morphine-6-glucuronide was conjugated to a decapeptide. The conjugated morphine had significantly higher and longer analgesic activity and passed blood brain barrier 100 times more than unconjugated morphine after 60 s perfusion in guinea pigs.

IT 454650-18-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pharmaceutical compns. comprising analgesic mol. linked to vector for mol. through hematoencephalic barrier)

RN 454650-18-1 CAPLUS

CN L-Phenylalanine, N2-[3-[[2-[[1-O-[(5α,6α)-7,8-didehydro-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-yl]-β-D-glucopyranuronoyl]amino]ethyl]dithio]-1-oxopropyl]-L-arginyl-L-arginyl-L-leucyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-B



L9 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:518937 CAPLUS
DOCUMENT NUMBER: 127:136035
TITLE: Glycoconjugates of opioids
INVENTOR(S): Cowie, Diana; Valencia Paera, Gregori
PATENT ASSIGNEE(S): Farmhispania, S.A., Spain; Cowie, Diana; Valencia Parera, Gregori
SOURCE: PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Spanish
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9721416	A2	19970619	WO 1996-ES214	19961115
WO 9721416	A3	19970912		
W: CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2211596	A1	19970619	CA 1996-2211596	19961115
EP 816375	A1	19980107	EP 1996-938222	19961115
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 10513485	T	19981222	JP 1996-521758	19961115
PRIORITY APPLN. INFO.:			ES 1995-2346 A	19951129

OTHER SOURCE(S): MARPAT 127:136035

AB Glycoconjugates of biol. active opioids were prepared which have at least one residue of carbohydrate linked to the opioid via an O- or C-glycoside bond. Thus, 6-morphinyl-β-D-glucopyranoside acetate was prepared by reaction of tetra-acetyl-α-D-glucopyranosyl bromide with 3-O-acetylmorphine, followed by saponification with MeONa-MeOH.

IT 192768-56-2P 192768-57-3P 192768-68-6P
192768-69-7P 192769-04-3P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of glycoconjugates of opioids)

RN 192768-56-2 CAPLUS

CN β-D-Glucopyranosiduronamide, (5α,6α)-7,8-didehydro-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-yl N-octyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192768-57-3 CAPLUS

CN β-D-Galactopyranosiduronamide, (5α,6α)-7,8-didehydro-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-yl N-octyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192768-68-6 CAPLUS

CN β-D-Glucopyranosiduronamide, (5α,6α)-7,8-didehydro-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192768-69-7 CAPLUS
CN β-D-Galactopyranosiduronamide, (5α,6α)-7,8-didehydro-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192769-04-3 CAPLUS
CN β-D-Glucopyranosiduronamide, (5α,6α)-7,8-didehydro-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-yl N-octyl-, monoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 192768-56-2
CMF C31 H44 N2 O8

Absolute stereochemistry.



CM 2

CRN 64-19-7

CMF C2 H4 O2



```
=> d his

     (FILE 'HOME' ENTERED AT 15:11:41 ON 19 NOV 2007)

     FILE 'REGISTRY' ENTERED AT 15:12:03 ON 19 NOV 2007
L1             STRUCTURE UPLOADED
L2           1 S L1 SSS SAM
L3          11 S L1 SSS FULL

     FILE 'CAPLUS, MEDLINE' ENTERED AT 15:14:33 ON 19 NOV 2007
L4           3 S L3
L5           2 S L4 AND PAIN

     FILE 'REGISTRY' ENTERED AT 15:51:39 ON 19 NOV 2007
L6             STRUCTURE UPLOADED
L7           1 S L6
L8          13 S L6 SSS FULL

     FILE 'CAPLUS, MEDLINE' ENTERED AT 15:54:54 ON 19 NOV 2007
L9           3 S L8
```